These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 23877438)

  • 1. CD74-ROS1 fusion transcripts in resected non-small cell lung carcinoma.
    Matsuura S; Shinmura K; Kamo T; Igarashi H; Maruyama K; Tajima M; Ogawa H; Tanahashi M; Niwa H; Funai K; Kohno T; Suda T; Sugimura H
    Oncol Rep; 2013 Oct; 30(4):1675-80. PubMed ID: 23877438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD74/SLC34A2-ROS1 Fusion Variants Involving the Transmembrane Region Predict Poor Response to Crizotinib in NSCLC Independent of TP53 Mutations.
    Li W; Fei K; Guo L; Wang Y; Shu C; Wang J; Ying J
    J Thorac Oncol; 2024 Apr; 19(4):613-625. PubMed ID: 38070598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and the prognostic characteristics of lung adenocarcinoma patients with ROS1 fusion in comparison with other driver mutations in East Asian populations.
    Chen YF; Hsieh MS; Wu SG; Chang YL; Shih JY; Liu YN; Tsai MF; Tsai TH; Yu CJ; Yang JC; Yang PC
    J Thorac Oncol; 2014 Aug; 9(8):1171-9. PubMed ID: 25157770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases.
    Yoshida A; Kohno T; Tsuta K; Wakai S; Arai Y; Shimada Y; Asamura H; Furuta K; Shibata T; Tsuda H
    Am J Surg Pathol; 2013 Apr; 37(4):554-62. PubMed ID: 23426121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multidriver mutation analysis in pulmonary mucinous adenocarcinoma in Taiwan: identification of a rare CD74-NRG1 translocation case.
    Gow CH; Wu SG; Chang YL; Shih JY
    Med Oncol; 2014 Jul; 31(7):34. PubMed ID: 24913807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
    Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
    Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.
    Shim HS; Kenudson M; Zheng Z; Liebers M; Cha YJ; Hoang Ho Q; Onozato M; Phi Le L; Heist RS; Iafrate AJ
    J Thorac Oncol; 2015 Aug; 10(8):1156-62. PubMed ID: 26200269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.
    Aisner DL; Nguyen TT; Paskulin DD; Le AT; Haney J; Schulte N; Chionh F; Hardingham J; Mariadason J; Tebbutt N; Doebele RC; Weickhardt AJ; Varella-Garcia M
    Mol Cancer Res; 2014 Jan; 12(1):111-8. PubMed ID: 24296758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
    Kim HR; Lim SM; Kim HJ; Hwang SK; Park JK; Shin E; Bae MK; Ou SH; Wang J; Jewell SS; Kang DR; Soo RA; Haack H; Kim JH; Shim HS; Cho BC
    Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
    Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A
    Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
    Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
    J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.
    Lin JJ; Ritterhouse LL; Ali SM; Bailey M; Schrock AB; Gainor JF; Ferris LA; Mino-Kenudson M; Miller VA; Iafrate AJ; Lennerz JK; Shaw AT
    J Thorac Oncol; 2017 May; 12(5):872-877. PubMed ID: 28088512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
    Kato Y; Ninomiya K; Ohashi K; Tomida S; Makimoto G; Watanabe H; Kudo K; Matsumoto S; Umemura S; Goto K; Ichihara E; Ninomiya T; Kubo T; Sato A; Hotta K; Tabata M; Toyooka S; Maeda Y; Kiura K
    Cancer Sci; 2018 Oct; 109(10):3149-3158. PubMed ID: 30053332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer.
    Li Z; Shen L; Ding D; Huang J; Zhang J; Chen Z; Lu S
    J Thorac Oncol; 2018 Jul; 13(7):987-995. PubMed ID: 29704675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A new target in non-small cell lung cancer: ROS1 fusion gene].
    Cai WJ; Su B
    Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):1-4. PubMed ID: 23648291
    [No Abstract]   [Full Text] [Related]  

  • 16. [Detection of ALK, ROS1 and RET fusion genes in non-small cell lung cancer patients and its clinicopathologic correlation].
    Zhong S; Zhang H; Bai D; Gao D; Zheng J; Ding Y
    Zhonghua Bing Li Xue Za Zhi; 2015 Sep; 44(9):639-43. PubMed ID: 26705279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.
    Katayama R; Kobayashi Y; Friboulet L; Lockerman EL; Koike S; Shaw AT; Engelman JA; Fujita N
    Clin Cancer Res; 2015 Jan; 21(1):166-74. PubMed ID: 25351743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.
    Davies KD; Le AT; Theodoro MF; Skokan MC; Aisner DL; Berge EM; Terracciano LM; Cappuzzo F; Incarbone M; Roncalli M; Alloisio M; Santoro A; Camidge DR; Varella-Garcia M; Doebele RC
    Clin Cancer Res; 2012 Sep; 18(17):4570-9. PubMed ID: 22919003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD74-ROS1 G2032R mutation transcriptionally up-regulates Twist1 in non-small cell lung cancer cells leading to increased migration, invasion, and resistance to crizotinib.
    Gou W; Zhou X; Liu Z; Wang L; Shen J; Xu X; Li Z; Zhai X; Zuo D; Wu Y
    Cancer Lett; 2018 May; 422():19-28. PubMed ID: 29477381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].
    Chen LF; Chen XY; Yu XB
    Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):221-5. PubMed ID: 27033383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.